The Dangers of Vaping: An Urgent Call for Awareness

Aug.03.2023
Vaping is equally or more dangerous than smoking, warns Dr. Faustino Aguilar Arocha, as it can lead to cancer and addiction.

Many young people are unaware, but "vaping" is equally or more dangerous than smoking due to the multiple chemical components present in the liquid used to give flavor and scent to the e-cigarettes, according to Dr. Faustino Aguilar Arocha. He stated that this new trend can lead to lung, mouth, and throat cancer due to excessive use of these devices.

 

The use of e-cigarettes is not safe for children, teenagers, or adults who have taken up this trend as a way to quit smoking. However, many of them are unaware that the damage caused to their health by using e-cigarettes can be just as harmful as smoking conventional cigarettes.

 

The head of jurisdiction 04 stated that e-cigarettes contain nicotine, along with other harmful substances that lead to addiction and frequent health issues. In most cases, the lungs, mouth, and throat are the affected areas.

 

"It is important that young people become aware and stop following the trend of using e-cigarettes, which are prohibited and should not be sold. Those who market and distribute them may be committing a crime due to the impact on public health," he warned.

 

He mentioned that in many cases, it is underage youth who adopt the use of e-cigarettes as a trend without knowing the damages it can cause. Therefore, parents are urged to monitor their children and prevent them from falling into this type of addiction, which can lead to frequent migraines, oral problems, and, most serious of all, lung, throat, or mouth cancer.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Documents obtained by 2Firsts show that Sweden's Public Health Agency ordered Swedish Match to revise ingredient labels beyond the five ZYN products inspected. The dispute centers on whether flavoring ingredients must be individually disclosed, with Swedish Match citing trade-secret protection and the regulator insisting on full ingredient disclosure. The company faces a conditional penalty of SEK 2 million per month for noncompliance. As of October 22, the agency had received no appeal, despite the company's stated intention to challenge the decision.
Oct.22
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
US-listed vaping technology and manufacturing company Ispire Technology reported fiscal first-quarter 2027 revenue of $27.5 million on November 9, 2026, down 9.3% year over year but up 3.2% sequentially. Gross margin recovered to 16.2%, while its net loss widened to $6.4 million from $3.3 million a year earlier. Management attributed the sales decline primarily to tighter European vaping regulation and reduced distributor orders. Ispire is expanding manufacturing in Malaysia and negotiating an OEM/ODM agreement with a Southeast Asian vaping brand, with an announcement anticipated in January 2027. The company estimates that Malaysian manufacturing offers an approximately 25% US tariff advantage over China-based production. However, it continues to purchase products from Shenzhen Yi Jia Technology Co., Ltd., a manufacturer controlled by its chairman, and reported $52 million in non-current related-party payables at September 30.
company
Nov.11 by 2Firsts Perspectives
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08